ReVas is dedicated to the research and development of therapeutic agents to be used with medical devices and biomaterials for the local non-systemic treatment of CVD. Together with our partner, Medtronic Inc., we aim to identify small molecules that will be used with drug-eluting stents (DES) to treat restenosis. Worldwide, more than 6 million patients have received DES since they were launched in 2002. This market has grown to approximately $5 billion USD within the last five years. We believe that by expanding our franchise into all stages of the disease we will maximize our ability to treat patients.

Drug Eluting Stent: Cross Section of Coronary Artery

Drug Eluting Stent: Architecture Components